IFM 99-02 Thalidomide in Myeloma
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
Multiple Myeloma
DRUG: Thalidomide|DRUG: Biphosphonates
Duration of response, 3 years
Survival, 3 years|Toxicity, 3 years
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma